Want to see AU:TLX full AI Analyst Report?
TLX Stock Chart & Stats
AU$14.64
-AU$0.59(-2.38%)
At close: 4:00 PM EST
AU$14.64
-AU$0.59(-2.38%)
Day’s Range― - ―
52-Week RangeAU$8.26 - AU$25.87
Previous CloseN/A
Volume456.62K
Average Volume (3M)2.05M
Market Cap
AU$5.83B
Enterprise ValueAU$5.37B
Total Cash (Recent Filing)AU$212.74M
Total Debt (Recent Filing)AU$699.77M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 20, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding339,378,850
10 Day Avg. Volume2,405,647
30 Day Avg. Volume2,050,857
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$25.20Price Target Upside72.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$967.95M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Commercial TractionSustained double-digit revenue growth and ambitious FY2026 guidance indicate durable commercial momentum and product-market fit. Rapid top-line scaling strengthens bargaining power with payers and providers, funds ongoing R&D, and provides a platform to amortize fixed costs as therapeutics and international sales scale over months to years.
High-margin Precision Medicine EngineA concentrated, high-margin commercial core provides structural cash conversion and profitability leverage. Precision Medicine's margin dominance supports self-funding of pipeline programmes, underpins group gross margin resiliency, and reduces the incremental funding burden for late-stage therapeutic development over the medium term.
Manufacturing & Supply Integration (RLS)In-house manufacturing and the RLS acquisition create a durable competitive advantage in radiopharmaceuticals where proximity and reliability matter. Vertical integration improves supply resilience, shortens time-to-patient for short‑half‑life products, and can protect margins and market share as volumes scale internationally over 2–6 months and beyond.
Bears Say
Rising LeverageMaterial rise in leverage reduces financial flexibility and raises refinancing and interest-rate risk if earnings falter. For a company still reinvesting heavily and facing binary regulatory outcomes, elevated debt increases the probability of external financing requirements or constrained strategic choices over the next several quarters.
Weakened Cash GenerationThe reversal to negative operating and free cash flow undermines the firm's ability to self-fund higher R&D guidance and manufacturing expansion. Persistent negative cash conversion increases reliance on external capital or slower investment pacing, elevating execution risk for pivotal trials and commercial launches over the medium term.
Regulatory & Approval Execution RiskPending resubmissions create binary outcomes and timing uncertainty for therapeutic revenue and clinical validation. Delays or adverse outcomes would postpone commercialization and returns on R&D spend, compress near-term cash flow improvement and complicate planning for pivotal launches and reimbursement negotiations across markets.
Telix Pharmaceuticals News
TLX FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest share price was AU$8.26 and its highest was AU$25.87 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is AU$5.83B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 48 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Feb 19, 2026. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of AU$0.058 by -AU$0.075.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.03.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 339,378,850 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of -AU$0.017 in its last earnings report, missing expectations of AU$0.058. Following the earnings report the stock price went up 14.239%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:TLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$25.20 (72.13% Upside)
AU$25.20 (72.13% Upside)
Blogger Sentiment
Bullish
AU:TLX Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.12%
12-Months-Change
Fundamentals
Return on Equity
-1.72%
Trailing 12-Months
Asset Growth
25.10%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
TLX Company Deck
TLX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive commercial and strategic picture: very strong top-line growth (56% FY2025), a high-margin, cash-generative Precision Medicine engine, successful recent FDA approval and launches, a deep late-stage pipeline with three pivotal therapeutic programs, and upgraded R&D investment to accelerate therapeutics. Offsetting these strengths are regulatory setbacks that require resubmissions (Pixclara and Zircaix), modest consolidated profitability due to aggressive reinvestment (adjusted EBITDA $39.5M), a lean year-end cash balance after major investments, and near-term concentration in the U.S. reimbursement environment. Management has outlined a clear plan to self-fund pipeline advancement and scale manufacturing, but execution and timing of regulatory approvals and the ramp of international reimbursement remain key risks.View all AU:TLX earnings summariesTLX Stock 12 Month Forecast
Average Price Target
AU$25.20
▲(72.13% Upside)
Technical Analysis
Imugene
―
Immutep Ltd
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―
Options Prices
Currently, No data available
---